ArticleEBioMedicine2021
SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity.
Article in EBioMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Landscape of epitopes targeted by T cells in 852 individuals recovered from COVID-19: Meta-analysis, immunoprevalence, and web platform.Cell reports. Medicine · 2021Pooled it
- Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles.Scientific reports · 2023Trial
- Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients.PloS one · 2022Trial
- Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Gut microbiota and tuberculosis.iMeta · 2025Review
- Persistent neurocognitive abnormalities as clinical sequelae of mild to moderate COVID-19.Frontiers in medicine · 2025Article
- Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19.The Journal of infectious diseases · 2024Article
- The HLA-II immunopeptidome of SARS-CoV-2.Cell reports · 2024Article
- The molecular mechanisms of CD8Frontiers in immunology · 2024Review
- FASTMAP-a flexible and scalable immunopeptidomics pipeline for HLA- and antigen-specific T-cell epitope mapping based on artificial antigen-presenting cells.Frontiers in immunology · 2024Article
- Omicron Variant-Specific Serological Imprinting Following BA.1 or BA.4/5 Bivalent Vaccination and Previous SARS-CoV-2 Infection: A Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study.BMC immunology · 2023Article
- SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection.iScience · 2023Article
- Article
- Cardiovascular complications of diabetes: role of non-coding RNAs in the crosstalk between immune and cardiovascular systems.Cardiovascular diabetology · 2023Review
- Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic.Archivum immunologiae et therapiae experimentalis · 2023Review
- Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants.Cell reports · 2023Article
- Discovery of neutralizing SARS-CoV-2 antibodies enriched in a unique antigen specific B cell cluster.PloS one · 2023Article
- Structural understanding of SARS-CoV-2 virus entry to host cells.Frontiers in molecular biosciences · 2023Review
- T cell immune memory after covid-19 and vaccination.BMJ medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe SARS-CoV-2 pandemic currently prevails worldwide. To understand the immunological signature of SARS-CoV-2 infections and aid the search and evaluation of new treatment modalities and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed.
methodsWe included 203 recovered SARS-CoV-2 infected patients in Denmark between April 3
findingsWe report broad serological profiles within the cohort, detecting antibody binding to other human coronaviruses. 202(>99%) participants had SARS-CoV-2 specific antibodies, with SARS-CoV-2 neutralization and spike-ACE2 receptor interaction blocking observed in 193(95%) individuals. A significant positive correlation (r=0.7804) between spike-ACE2 blocking antibody titers and neutralization potency was observed. Further, SARS-CoV-2 specific CD8
interpretationThe viral surface spike protein was identified as the dominant target for both neutralizing antibodies and CD8
fundingThis study was supported by the Danish Ministry for Research and Education (grant# 0238-00001B) and The Danish Innovation Fund (grant# 0208-00018B).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.